Marshall Wace’s IGC Pharma IGC Stock Holding History

Marshall Wace’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,750	Closed	-$31K	–	4054
2021 Q3	$31K	Buy	+20,750	New	+$33.5K	﹤0.01%	2950

Other funds holding IGC

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace's IGC Position: Q4 2021 in Review

Marshall Wace sold out of IGC Pharma (IGC) in Q4 2021, closing a stake of 20,750 shares — an estimated $31K sold.

Marshall Wace first reported a position in IGC in Q3 2021 and held it in 1 quarter. The position peaked at $31K in Q3 2021. 29 funds tracked by Wall St. Rank hold IGC as of Q4 2021.

Marshall Wace reported no remaining IGC Pharma position as of Q4 2021 after selling out during the quarter.
Marshall Wace sold 20,750 IGC Pharma shares in Q4 2021, an estimated $31K.
Marshall Wace first reported a position in IGC Pharma in Q3 2021 and held it in 1 quarter.
Marshall Wace's IGC Pharma position peaked at $31K in Q3 2021.
29 funds tracked by Wall St. Rank held IGC Pharma as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.